Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma

American Journal of Clinical Pathology

Volumn 113, Issue 5, 2000, Pages 669-674

  Vang, R ^a   Cooley, L D ^a   Harrison, W R ^a   Reese, T ^a   Abrams, J ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Breast carcinoma; C erbB2; FISH; Fluorescence in situ hybridization; HER 2 neu; Immunohistochemistry

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TAB 250; PARAFFIN; POLYCLONAL ANTIBODY; POLYCLONAL ANTIBODY PC 11; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; VALIDATION PROCESS;

ANTIBODIES; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL MEMBRANE; CHROMOSOMES, HUMAN, PAIR 17; COSTS AND COST ANALYSIS; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2;

EID: 0034425264     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/LTUM-QG95-YRY3-L96U     Document Type: Article

References (32)

1. The neu-protein and breast cancer
2. Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma
3. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
4. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
5. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER-2/neu overexpressing human breast cancer xenografts
6. Monoclonal antibody to HER-2/neu gene product potentiates cytotoxicity of carboplatin and doxorubicin in human breast tumor cells
7. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
8. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAFT with tamoxifen (T) alone
9. 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erbB-B2 expression and tamoxifen efficacy
10. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
11. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
12. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
13. Pathological prognostic factors in breast cancer, I: The value of histological grade in breast cancer: Experience from a large study with long-term follow-up
14. Determining HER2/neu expression in breast carcinoma
15. The avidin-biotin complex (ABC) method and other avidin-biotin binding methods
16. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer
17. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
18. Proto-oncogene abnormalities in human breast cancer: c-erbB-2 amplification does not correlate with recurrence of disease
19. Correlation between ploidy status, ERB-B2 and p53 immunohistochemical expression in primary breast carcinoma
20. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation
21. Efficacy and safety of Herceptin (humanized anti-HER-2 antibody) as a single agent in 222 women with HER-2 overexpression who relapsed following chemotherapy for metastatic breast cancer
22. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system
23. Increased HER-2 with US Food and Drug Administration-approved antibody
24. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product
25. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
26. Detection and quantification of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
27. The combination of in-situ hybridization and immunohistochemical analysis: An evaluation of HER-2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium
28. Immunohistochemical study on the expression of c-erbB-2 oncoprotein in breast cancer
29. Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry
30. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer
31. Prognostic and predictive factors in breast cancer by immunohistochemical analysis
32. Immunohistochemical assay of neu/c-erb-2 oncogene product in paraffin-embedded tissues in early breast cancer: Retrospective follow-up study of 245 stage I and II cases